Sichuan, China

Hai Hu

This inventor holds 1 USPTO granted patent. Top assignee: Chengdu Sintanovo Biotechnology Co., Ltd.. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hai Hu. Retrieved from https://idiyas.com/inventor/hai-hu-ukksn358

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Inventor Hai Hu

Introduction

Hai Hu is a notable inventor based in Sichuan, China. He has made significant contributions to the field of biotechnology, particularly in the development of pharmaceutical compounds. His work focuses on polypeptide compounds that have the potential to advance clinical applications.

Latest Patents

Hai Hu holds a patent for a polypeptide compound, pharmaceutical composition, preparation method, and application thereof. The invention discloses a polypeptide compound that acts as a κ-opioid receptor agonist. This compound demonstrates better activity and shows promise as a clinical candidate. The structural formula of the polypeptide compound is represented in general formula (I). He has 1 patent to his name.

Career Highlights

Hai Hu is currently employed at Chengdu Sintanovo Biotechnology Co., Ltd. His role involves research and development of innovative pharmaceutical solutions. His expertise in polypeptide compounds positions him as a valuable asset in the biotechnology sector.

Collaborations

Hai Hu collaborates with notable colleagues, including Jian Gao and Xiaoping Fu. Their combined efforts contribute to the advancement of their research projects and the development of new pharmaceutical applications.

Conclusion

Hai Hu's innovative work in the field of biotechnology, particularly with polypeptide compounds, showcases his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in pharmaceutical development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…